Financial reports
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
6 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
4 Jan 24
8-K
Regulation FD Disclosure
15 Dec 23
8-K
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
7 Dec 23
8-K
Regulation FD Disclosure
9 Nov 23
8-K
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Regulation FD Disclosure
2 Oct 23
8-K
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
28 Sep 23
8-K
Regulation FD Disclosure
5 Sep 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
8 Dec 23
424B5
Prospectus supplement for primary offering
6 Dec 23
S-8
Registration of securities for employees
9 Nov 23
S-8
Registration of securities for employees
9 Nov 23
S-8
Registration of securities for employees
10 Nov 22
424B5
Prospectus supplement for primary offering
14 Jun 22
S-3
Shelf registration
3 Mar 22
S-8
Registration of securities for employees
10 Nov 21
S-8
Registration of securities for employees
31 Aug 21
424B5
Prospectus supplement for primary offering
23 Sep 20
Proxies
DEF 14A
Definitive proxy
26 Jun 23
DEF 14A
Definitive proxy
29 Jun 22
DEF 14A
Definitive proxy
28 Jun 21
DEF 14A
Definitive proxy
26 Jun 20
DEF 14A
Definitive proxy
26 Jun 19
DEF 14A
Definitive proxy
28 Jun 18
DEF 14A
Definitive proxy
6 Jul 17
DEF 14A
Definitive proxy
15 Jul 16
Other
EFFECT
Notice of effectiveness
5 May 22
CORRESP
Correspondence with SEC
2 May 22
UPLOAD
Letter from SEC
7 Mar 22
EFFECT
Notice of effectiveness
4 May 20
UPLOAD
Letter from SEC
6 Dec 19
CORRESP
Correspondence with SEC
3 Dec 19
UPLOAD
Letter from SEC
27 Nov 19
EFFECT
Notice of effectiveness
15 Aug 19
CORRESP
Correspondence with SEC
12 Aug 19
UPLOAD
Letter from SEC
9 Aug 19
Ownership
4
Kyle Moran
5 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
SC 13G/A
MAVERICK CAPITAL LTD
14 Feb 24
SC 13G/A
683 Capital Management, LLC
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
M28 Capital Management LP
12 Feb 24
4
Chris Francis
7 Feb 24
4
PAUL BOLNO
7 Feb 24
4
Kyle Moran
7 Feb 24
4
Chandra Vargeese
7 Feb 24